Molecular Templates Inc MTEM
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if MTEM is a good fit for your portfolio.
News
-
Molecular Templates Presents Interim Data from MT-6402 Phase I Study in Patients with PD-L1+ Solid Tumors at the 2024 American Association for Cancer Research (AACR) Annual Meeting; Monotherapy Activity in Checkpoint-Experienced Head and Neck Cancer Patients Observed Through Novel Immuno-oncology Mechanism
-
Molecular Templates, Inc. Reports Fourth Quarter 2023 Financial Results and Business Update
-
Molecular Templates Announces $9.5 Million Private Placement Offering and Agreement to Amend Second Tranche of July 2023 Purchase Agreement
-
Molecular Templates, Inc. Provides Interim Update
-
Molecular Templates to Present at Oppenheimer 34th Annual Healthcare Life Sciences Conference
Trading Information
- Previous Close Price
- $1.50
- Day Range
- $1.45–1.59
- 52-Week Range
- $1.40–9.45
- Bid/Ask
- $1.51 / $1.67
- Market Cap
- $10.21 Mil
- Volume/Avg
- 23,617 / 70,124
Key Statistics
- Price/Earnings (Normalized)
- 2.10
- Price/Sales
- 0.13
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Molecular Templates Inc is a clinical-stage biopharmaceutical company focused on developing therapeutic agents that selectively target tumor cells for the treatment of individuals living with cancer. Its pipeline products are MT-6402, MT-8421 and MT-0169.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 62
- Website
- https://www.mtem.com
Competitors
Valuation
|
Metric
|
MTEM
|
LLY
|
RHHBY
|
|---|---|---|---|
Price/Earnings (Normalized) | 2.10 | 88.87 | 11.47 |
Price/Book Value | 1.98 | 65.72 | 5.71 |
Price/Sales | 0.13 | 19.74 | 2.99 |
Price/Cash Flow | 3.58 | 92.33 | 10.99 |
Price/Earnings
MTEM
LLY
RHHBY
Financial Strength
|
Metric
|
MTEM
|
LLY
|
RHHBY
|
|---|---|---|---|
Quick Ratio | 0.68 | 0.52 | 0.99 |
Current Ratio | 0.97 | 0.94 | 1.35 |
Interest Coverage | −2.52 | 14.13 | 14.93 |
Quick Ratio
MTEM
LLY
RHHBY
Profitability
|
Metric
|
MTEM
|
LLY
|
RHHBY
|
|---|---|---|---|
Return on Assets (Normalized) | −8.94% | 10.22% | 17.03% |
Return on Equity (Normalized) | — | 52.03% | 53.42% |
Return on Invested Capital (Normalized) | −15.35% | 19.27% | 26.30% |
Return on Assets
MTEM
LLY
RHHBY
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Hdlxdlrpv | Mhyy | $557.8 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Dtfyytns | Hbwsqh | $104.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Nbdtjlv | Phjzwl | $99.6 Bil | |
MRNA
| Moderna Inc | Fddzqdts | Wzfmh | $38.8 Bil | |
ARGX
| argenx SE ADR | Vyldkgbk | Kpdz | $21.4 Bil | |
BNTX
| BioNTech SE ADR | Jcrfvqcq | Lrhys | $21.3 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Szbfxgkwf | Ttqncw | $18.4 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Nnxpgwr | Rrtjx | $17.5 Bil | |
RPRX
| Royalty Pharma PLC Class A | Zmfzttfqv | Hmxwzm | $12.4 Bil | |
INCY
| Incyte Corp | Rtczdlmk | Vshxgz | $11.9 Bil |